Association between the low percentage of forced vital capacity and increased mortality after left ventricular assist device implantation
- PMID: 33403129
- PMCID: PMC7759045
- DOI: 10.5606/tgkdc.dergisi.2020.19768
Association between the low percentage of forced vital capacity and increased mortality after left ventricular assist device implantation
Abstract
Background: This study aims to investigate the effect of low percentage of forced vital capacity measured in the preoperative period on the 28-day mortality in patients undergoing left ventricular assist device implantation.
Methods: A total of 131 patients (111 males, 20 females; median age 54 years; range, 47 to 59 years) who underwent left ventricular assist device implantation with HeartWare™ between December 2010 and January 2016 were retrospectively analyzed. The patients were divided into two groups according to the results of pulmonary function test as a forced vital capacity percentage of ≥60% (n=113) and <60% (n=18). Both groups were compared in terms of laboratory and clinical characteristics, and postoperative complications. Risk factors for postoperative 28-day mortality were analyzed.
Results: Pre- and intraoperative characteristics were similar in both groups, except for left ventricular end-diastolic diameter. The ventilator-free days up to 28 days was shorter (p=0.046) and the length of intensive care unit stay was longer (p=0.011) in the low percentage of forced vital capacity group. The 28-day mortality rate was also higher (22.2% vs. 9.7%, respectively; p=0.12) in this group. The history of prior cardiac operation (odds ratio: 4.40; 95% confidence interval 1.19-16.20, p=0.026) and tricuspid valve repair at the time of device implantation (odds ratio: 5.30; 95% confidence interval 1.33-21.00, p=0.018) were found to be independent risk factors for mortality. Multivariate analysis showed that a forced vital capacity of <60% was not associated with mortality (odds ratio: 3.96; 95% confidence interval 0.95-16.43, p=0.058).
Conclusion: The length of intensive care unit stay and duration of mechanical ventilation may be longer in patients with a low percentage of forced vital capacity. Although the association between 28-day mortality and low percentage of forced vital capacity is not significant, the risk of 28-day mortality is higher in this group. Therefore, the patients should be assessed carefully before the left ventricular assist device operation.
Keywords: Complication; heart failure; heart-assist device; mortality; pulmonary function test.
Copyright © 2020, Turkish Society of Cardiovascular Surgery.
Conflict of interest statement
Conflict of Interest: The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.
Figures
Similar articles
-
Pulmonary function tests do not predict mortality in patients undergoing continuous-flow left ventricular assist device implantation.J Thorac Cardiovasc Surg. 2017 Dec;154(6):1959-1970.e1. doi: 10.1016/j.jtcvs.2017.02.069. Epub 2017 Apr 11. J Thorac Cardiovasc Surg. 2017. PMID: 28526500
-
Durability and clinical impact of tricuspid valve procedures in patients receiving a continuous-flow left ventricular assist device.J Thorac Cardiovasc Surg. 2016 Feb;151(2):520-7.e1. doi: 10.1016/j.jtcvs.2015.09.082. Epub 2015 Sep 28. J Thorac Cardiovasc Surg. 2016. PMID: 26806510
-
Prolonged mechanical ventilation after left ventricular assist device implantation: risk factors and clinical implications.ESC Heart Fail. 2019 Jun;6(3):545-551. doi: 10.1002/ehf2.12428. Epub 2019 Mar 12. ESC Heart Fail. 2019. PMID: 30861636 Free PMC article.
-
Left ventricular assist device implantation with and without concomitant tricuspid valve surgery: a systematic review and meta-analysis.Eur J Cardiothorac Surg. 2018 Oct 1;54(4):644-651. doi: 10.1093/ejcts/ezy150. Eur J Cardiothorac Surg. 2018. PMID: 29897441
-
Frailty and Clinical Outcomes in Advanced Heart Failure Patients Undergoing Left Ventricular Assist Device Implantation: A Systematic Review and Meta-analysis.J Am Med Dir Assoc. 2018 Mar;19(3):255-261.e1. doi: 10.1016/j.jamda.2017.09.022. Epub 2017 Nov 9. J Am Med Dir Assoc. 2018. PMID: 29129497
References
-
- Wieselthaler GM, O Driscoll G, Jansz P, Khaghani A, Strueber M, HVAD Clinical Investigators Initial clinical experience with a novel left ventricular assist device with a magnetically levitated rotor in a multi-institutional trial. J Heart Lung Transplant. 2010;29:1218–1225. - PubMed
-
- Lietz K, Long JW, Kfoury AG, Slaughter MS, Silver MA, Milano CA, et al. Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: implications for patient selection. Circulation. 2007;116:497–505. - PubMed
-
- Birks EJ, George RS, Hedger M, Bahrami T, Wilton P, Bowles CT, et al. Reversal of severe heart failure with a continuousflow left ventricular assist device and pharmacological therapy: a prospective study. Circulation. 2011;123:381–390. - PubMed
-
- Meyer AL, Malehsa D, Bara C, Haverich A, Strueber M. Implantation of rotary blood pumps into 115 patients: a singlecentre experience. Eur J Cardiothorac Surg. 2013;43:1233–1236. - PubMed
-
- Slaughter MS, Rogers JG, Milano CA, Russell SD, Conte JV, Feldman D, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009;361:2241–2251. - PubMed
LinkOut - more resources
Full Text Sources